Neuronetics, Inc.

Neuronetics Inc. is a company specializing in the development and commercialization of non-invasive treatment solutions for psychiatric disorders, particularly major depressive disorder (MDD). The primary focus of Neuronetics Inc. is its NeuroStar Advanced Therapy System, which utilizes transcranial magnetic stimulation (TMS) technology to deliver targeted magnetic pulses to stimulate nerve cells in the brain. This technology is an alternative for patients who have not responded well to traditional medication treatments for depression. Neuronetics’ innovation significantly impacts the healthcare sector, particularly mental health care, by providing a drug-free treatment option that has wide acceptance in clinical settings. The company plays a key role in the market by addressing a substantial unmet medical need, offering hope and options for a large demographic affected by depression. Headquartered in Malvern, Pennsylvania, Neuronetics Inc. supports healthcare providers through training, support services, and a network that facilitates broad adoption of its therapies. The company aligns with growing trends in personalized medicine and mental health awareness, maintaining a significant presence in both domestic and international markets within the medical devices industry.